Methylprednisolone for prevention of ovarian hyperstimulation syndrome in patients with polycystic ovarian syndrome undergoing in-vitro fertilisation: a randomised controlled trial

References

• Agrawal R, Sladkevicius P, Engmann L, Conway GS, Payne NN, Bekis J, et al. 1998. Serum vascular endothelial growth factor concentrations and ovarian stromal blood flow are increased in women with polycystic ovaries. Human Reproduction 13:651–655.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. 1998. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clinical Science 94:557–572.
   PubMed Web of Science ®Google Scholar
• Bhathena RK. 1998. The pathophysiology, prevention and management of the ovarian hyperstimulation syndrome. Journal of Obstetrics and Gynaecology: The Journal of the Institute of Obstetrics and Gynaecology 18:405–407.
   PubMedGoogle Scholar
• Boland EW. 1962. Clinical comparison of the newer anti-inflammatory corticosteroids. Annals of the Rheumatic Diseases 21:176–187.
   PubMed Web of Science ®Google Scholar
• Boomsma CM, Keay SD, Macklon NS. 2012. Peri-implantation glucocorticoid administration for assisted reproductive technology cycles. Cochrane Database of Systematic Reviews 6:CD005996.
   Google Scholar
• Calabro RS, Gervasi G, Leo A, De Luca R, Balletta T, Casella C, et al. 2014. Neurovascular complications of ovarian hyperstimulation syndrome (OHSS): from pathophysiology to recent treatment options. Recent Patents on Endocrine, Metabolic and Immune Drug Discovery 8:109–116.
   PubMedGoogle Scholar
• Cohen J, Malter H, Elsner C, Kort H, Massey J, Mayer MP. 1990. Immunosuppression supports implantation of zona pellucida dissected human embryos. Fertility and Sterility 53:662–665.
   PubMed Web of Science ®Google Scholar
• Delvigne A, Rozenberg S. 2002. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Human Reproduction Update 8:559–577.
   PubMed Web of Science ®Google Scholar
• Garcia-Velasco JA, Isaza V, Quea G, Pellicer A. 2006. Coasting for the prevention of ovarian hyperstimulation syndrome: much ado about nothing? Fertility and Sterility 85:547–554.
   PubMed Web of Science ®Google Scholar
• Golan A, Ron-El R, Herman A, Soffer Y, Weinraub Z, Caspi E. 1989. Ovarian hyperstimulation syndrome: an update review. Obstetrical and Gynecological Survey 44:430–440.
   PubMedGoogle Scholar
• Griesinger G, Schultz L, Bauer T, Broessner A, Frambach T, Kissler S. 2011. Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing hormone antagonist protocol in combination with a “freeze-all” strategy: a prospective multicentric study. Fertility and Sterility 95:2029–2033. 2033 e2021.
   PubMed Web of Science ®Google Scholar
• Humaidan P, Quartarolo J, Papanikolaou EG. 2010. Preventing ovarian hyperstimulation syndrome: guidance for the clinician. Fertility and Sterility 94:389–400.
   PubMed Web of Science ®Google Scholar
• Lainas T, Petsas G, Stavropoulou G, Alexopoulou E, Iliadis G, Minaretzis D. 2002. Administration of methylprednisolone to prevent severe ovarian hyperstimulation syndrome in patients undergoing in vitro fertilization. Fertility and Sterility 78:529–533.
   PubMed Web of Science ®Google Scholar
• Lew W, Oppenheim JJ, Matsushima K. 1988. Analysis of the suppression of IL-1 alpha and IL-1 beta production in human peripheral blood mononuclear adherent cells by a glucocorticoid hormone. Journal of Immunology 140:1895–1902.
   PubMed Web of Science ®Google Scholar
• Nastri CO, Ferriani RA, Rocha IA, Martins WP. 2010. Ovarian hyperstimulation syndrome: pathophysiology and prevention. Journal of Assisted Reproduction and Genetics 27:121–128.
   PubMed Web of Science ®Google Scholar
• Nauck M, Karakiulakis G, Perruchoud AP, Papakonstantinou E, Roth M. 1998. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. European Journal of Pharmacology 341:309–315.
   PubMed Web of Science ®Google Scholar
• Peitsidis P, Agrawal R. 2010. Role of vascular endothelial growth factor in women with PCO and PCOS: a systematic review. Reproductive Biomedicine Online 20:444–452.
   PubMed Web of Science ®Google Scholar
• Polak De Fried E, Blanco L, Lancuba S, Asch RH. 1993. Improvement of clinical pregnancy rate and implantation rate of in-vitro fertilization-embryo transfer patients by using methylprednisone. Human Reproduction (Oxford, England) 8:393–395.
   PubMed Web of Science ®Google Scholar
• Revelli A, Dolfin E, Gennarelli G, et al. 2008. Low-dose acetylsalicylic acid plus prednisolone as an adjuvant treatment in IVF: a prospective, randomized study. Fertility and Sterility 90:1685–1691.
   PubMed Web of Science ®Google Scholar
• Rotterdam Ea-SPCWG. 2004. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility and Sterility 81:19–25.
   Web of Science ®Google Scholar
• Swanton A, Storey L, Mcveigh E, Child T. 2010. IVF outcome in women with PCOS, PCO and normal ovarian morphology. European Journal of Obstetrics, Gynecology and Reproductive Biology 149:68–71.
   PubMed Web of Science ®Google Scholar
• Tan SL, Balen A, El Hussein E, Campbell S, Jacobs HS. 1992. The administration of glucocorticoids for the prevention of ovarian hyperstimulation syndrome in in vitro fertilization: a prospective randomized study. Fertility and Sterility 58:378–383.
   PubMed Web of Science ®Google Scholar
• Whelan JG, 3rd, Vlahos NF. 2000. The ovarian hyperstimulation syndrome. Fertility and Sterility 73:883–896.
   PubMed Web of Science ®Google Scholar
• Zhang FL, Fu LL, Yang Y. 2016. Both thromboembolic stroke and cerebral venous thrombosis resulting from Ovarian Hyperstimulation Syndrome (OHSS). Journal of Obstetrics and Gynaecology: The Journal of the Institute of Obstetrics and Gynaecology 36:267–268.
   PubMedGoogle Scholar